BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 17936837)

  • 1. Serum tumor markers may predict overall and disease specific survival in patients with clinically organ confined invasive bladder cancer.
    Margel D; Tal R; Baniel J
    J Urol; 2007 Dec; 178(6):2297-300; discussion 2300-1. PubMed ID: 17936837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of extravesical disease by preoperative serum markers in patients with clinically organ confined invasive bladder cancer.
    Margel D; Tal R; Neuman A; Konichezky M; Sella A; Baniel J
    J Urol; 2006 Apr; 175(4):1253-7; discussion 1257. PubMed ID: 16515972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical use of serum CA-125 levels in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder.
    Kouba EJ; Lentz A; Wallen EM; Pruthi RS
    Urol Oncol; 2009; 27(5):486-90. PubMed ID: 18555706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphovascular invasion is independently associated with poor prognosis in patients with localized upper urinary tract urothelial carcinoma treated surgically.
    Saito K; Kawakami S; Fujii Y; Sakura M; Masuda H; Kihara K
    J Urol; 2007 Dec; 178(6):2291-6; discussion 2296. PubMed ID: 17936818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach.
    Garcia del Muro X; Condom E; Vigués F; Castellsagué X; Figueras A; Muñoz J; Solá J; Soler T; Capellà G; Germà JR
    Cancer; 2004 May; 100(9):1859-67. PubMed ID: 15112266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy.
    Lotan Y; Gupta A; Shariat SF; Palapattu GS; Vazina A; Karakiewicz PI; Bastian PJ; Rogers CG; Amiel G; Perotte P; Schoenberg MP; Lerner SP; Sagalowsky AI
    J Clin Oncol; 2005 Sep; 23(27):6533-9. PubMed ID: 16116151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival.
    Dotan ZA; Kavanagh K; Yossepowitch O; Kaag M; Olgac S; Donat M; Herr HW
    J Urol; 2007 Dec; 178(6):2308-12; discussion 2313. PubMed ID: 17936804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of american joint committee on cancer pathological stage T2a versus T2b urothelial carcinoma: analysis of patient outcomes in organ confined bladder cancer.
    Boudreaux KJ; Clark PE; Lowrance WT; Rumohr JA; Barocas DA; Cookson MS; Smith JA; Chang SS
    J Urol; 2009 Feb; 181(2):540-5; discussion 546. PubMed ID: 19084855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment delay and prognosis in invasive bladder cancer.
    Liedberg F; Anderson H; Månsson W
    J Urol; 2005 Nov; 174(5):1777-81; discussion 1781. PubMed ID: 16217282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer.
    Andrews B; Shariat SF; Kim JH; Wheeler TM; Slawin KM; Lerner SP
    J Urol; 2002 Mar; 167(3):1475-81. PubMed ID: 11832773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carcinoma in a bladder diverticulum: presentation and treatment outcome.
    Golijanin D; Yossepowitch O; Beck SD; Sogani P; Dalbagni G
    J Urol; 2003 Nov; 170(5):1761-4. PubMed ID: 14532771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum CYFRA 21-1 in patients with invasive bladder cancer and its relevance as a tumor marker during chemotherapy.
    Andreadis C; Touloupidis S; Galaktidou G; Kortsaris AH; Boutis A; Mouratidou D
    J Urol; 2005 Nov; 174(5):1771-5; discussion 1775-6. PubMed ID: 16217281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
    Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens.
    Kunju LP; You L; Zhang Y; Daignault S; Montie JE; Lee CT
    J Urol; 2008 Nov; 180(5):1928-32; discussion 1932. PubMed ID: 18801529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Independent predictors of cancer-specific survival in transitional cell carcinoma of the upper urinary tract: multi-institutional dataset from 3 European centers.
    Novara G; De Marco V; Gottardo F; Dalpiaz O; Bouygues V; Galfano A; Martignoni G; Patard JJ; Artibani W; Ficarra V
    Cancer; 2007 Oct; 110(8):1715-22. PubMed ID: 17724728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy.
    Yu RJ; Stein JP; Cai J; Miranda G; Groshen S; Skinner DG
    J Urol; 2006 Aug; 176(2):493-8; discussion 498-9. PubMed ID: 16813876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple adverse histological features increase the odds of under staging T1 bladder cancer.
    Weizer AZ; Wasco MJ; Wang R; Daignault S; Lee CT; Shah RB
    J Urol; 2009 Jul; 182(1):59-65; discussion 65. PubMed ID: 19447443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. External validation of a biomarker based pre-cystectomy algorithm to predict nonorgan confined urothelial cancers.
    Margel D; Bostrom P; Baniel J; Yossepowitch O; Zlotta A; Fleshner N
    J Urol; 2012 Mar; 187(3):840-4. PubMed ID: 22245328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder.
    Rogers CG; Palapattu GS; Shariat SF; Karakiewicz PI; Bastian PJ; Lotan Y; Gupta A; Vazina A; Gilad A; Sagalowsky AI; Lerner SP; Schoenberg MP
    J Urol; 2006 Jun; 175(6):2048-53; discussion 2053. PubMed ID: 16697800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.
    Shariat SF; Tokunaga H; Zhou J; Kim J; Ayala GE; Benedict WF; Lerner SP
    J Clin Oncol; 2004 Mar; 22(6):1014-24. PubMed ID: 14981102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.